Skip to main content
. 2013 Aug 28;9:1273–1280. doi: 10.2147/NDT.S48158

Table 2.

Change from baseline in MADRS total score at week 8 (ITT–LOCF)

Treatment group n Adjusted mean SE Difference vs placebo
Mean SE Order of test Adjusted 95% CI Adjusted P-value
Placebo 186 −13.9 0.77
BUP150 190 −14.4 0.77 −0.5 1.00 1 −2.7, 1.7 0.853
BUP300 188 −12.9 0.76 1.0 1.00 2 N/A N/A

Notes: CIs and the adjusted P-values were based on Dunnett’s step-down procedure. The statistical model included treatment group, region (country), and baseline value as explanatory variables. Since the first comparison (placebo vs BUP150) failed to show significance, the second comparison (placebo vs BUP300) was not performed, in order to control type I error rate.

Abbreviations: BUP150, bupropion SR 150 mg/day (once daily); BUP300, bupropion SR 150 mg/day (twice daily); CI, confidence interval; ITT–LOCF, intent-to-treat, last observation carried forward; MADRS, Montgomery–Åsberg Depression Rating Scale; N/A, not applicable; SE, standard error; SR, sustained release; n, number; vs, versus.